MUC1 and neoplasm: Of all the identified molecular alterations in HNSCCs, as per the NCI’s priority ranking of tumor antigens and the subsequently emerged literature, the most relevant antigens for the development of therapeutic vaccines are HPV E6/E7, EGFR, MAGE, p53, p16, WT1, MUC1, and LMP2 [2,6,33].